Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00381238 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00381238 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants.
The verdict
NCT00381238, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
Interventions
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-06-20 |
| Est. Completion | 2009-02-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00381238
The ClinicalTrials.gov registry entry for NCT00381238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone is the first listed.
NCT00381238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00381238 about?
NCT00381238 is a clinical study titled "Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease". This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT00381238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2006-06-20. Estimated completion is 2009-02-03.
What interventions are being tested in trial NCT00381238?
The interventions under investigation include: rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00381238?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.